Novo Nordisk

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• 
  Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals (öffnet in neuem Tab)

  Stocktwits · 03.10.2026

• 
  Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long (öffnet in neuem Tab)

  Stocktwits · 02.10.2026

• 
  Anthropic Is Spending $100M To Build The AI Workforce It Needs For Its Next Phase (öffnet in neuem Tab)

  Stocktwits · 02.10.2026

• 
  Novo provides update on the denecimig Biologics License Application (BLA) in the US (öffnet in neuem Tab)

  GlobeNewswire · 02.10.2026

• 
  Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors (öffnet in neuem Tab)

  Motley Fool · 02.10.2026

• 
  Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? (öffnet in neuem Tab)

  Motley Fool · 02.10.2026

• 
  DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care (öffnet in neuem Tab)

  Zacks · 02.10.2026

• 
  Agios' Growth Story Hinges on Mitapivat's Commercial Expansion (öffnet in neuem Tab)

  Zacks · 02.10.2026

• 
  Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker (öffnet in neuem Tab)

  24/7 Wall St. · 02.10.2026

• 
  3 drug targets pharma is betting on next (öffnet in neuem Tab)

  Pharma Voice · 02.10.2026

• 
  LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies (öffnet in neuem Tab)

  Zacks · 02.10.2026

• 
  How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market (öffnet in neuem Tab)

  Barrons.com · 01.10.2026

• Novo's Wegovy Pill Shows Weight Loss After Switching From Injections (öffnet in neuem Tab)

  01.10.2026

• Eli Lilly obesity drug data adds pressure on Novo Nordisk (öffnet in neuem Tab)

  01.10.2026

• Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win (öffnet in neuem Tab)

  01.10.2026

• Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026 (öffnet in neuem Tab)

  01.10.2026

• Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy (öffnet in neuem Tab)

  30.09.2026

• Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. (öffnet in neuem Tab)

  30.09.2026

• Novo inngår milliardsamarbeid med svenske Nanexa (öffnet in neuem Tab)

  MEDWATCH.no · 25.09.2026

• Novo inngår milliardavtale om svensk teknologi (öffnet in neuem Tab)

  Dagens Medisin · 25.09.2026

• Novo kan bli møtt med millionkrav (öffnet in neuem Tab)

  Finansavisen · 25.09.2026

• Novo Nordisk inngår milliardavtale med Nanexa (öffnet in neuem Tab)

  Finansavisen · 24.09.2026

• Novo åpner for USA-notering (öffnet in neuem Tab)

  Finansavisen · 23.09.2026

• Novo Nordisk-sjef vurderer M&A og pilledrevet fremtid etter investorreaksjon (öffnet in neuem Tab)

  Invezz · 22.09.2026

• Novo Nordisk vil utvide – aksjen faller (öffnet in neuem Tab)

  Dagens Medisin · 22.09.2026

• Novo-sjefen: – Da mister man tillit veldig raskt (öffnet in neuem Tab)

  Finansavisen · 22.09.2026

• Novo-aksjen faller 6 %: plan for nye blockbuster-legemidler og $23B-mål skuffer (öffnet in neuem Tab)

  Invezz · 21.09.2026

• Novo skuffer investorene – aksjen faller kraftig (öffnet in neuem Tab)

  Finansavisen · 21.09.2026

• Novo Nordisk-aksjen stuper (öffnet in neuem Tab)

  E24 · 21.09.2026

• DNB Carnegies anbefaling på Novo Nordisk (öffnet in neuem Tab)

  DNB · 21.09.2026